Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2020 | 1 |
2021 | 2 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Kidney Int. 2021 Jul;100(1):225-237. doi: 10.1016/j.kint.2020.10.046. Epub 2020 Dec 8.
Kidney Int. 2021.
PMID: 33307104
Free article.
Clinical Trial.
Convection Enhanced Delivery in the Setting of High-Grade Gliomas.
Nwagwu CD, Immidisetti AV, Jiang MY, Adeagbo O, Adamson DC, Carbonell AM.
Nwagwu CD, et al. Among authors: adeagbo o.
Pharmaceutics. 2021 Apr 15;13(4):561. doi: 10.3390/pharmaceutics13040561.
Pharmaceutics. 2021.
PMID: 33921157
Free PMC article.
Review.
Item in Clipboard
Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237.
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group.
Ariceta G, et al.
Kidney Int. 2023 Jul;104(1):205. doi: 10.1016/j.kint.2023.04.010.
Kidney Int. 2023.
PMID: 37349053
Free article.
No abstract available.
Item in Clipboard
Cite
Cite